Wallace Eli M. 4
4 · BridgeBio Oncology Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Wallace Eli M.
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2026-01-01+1,114,400→ 1,114,400 totalExercise: $12.52Exp: 2035-12-31→ Common Stock (1,114,400 underlying)
Footnotes (1)
- [F1]69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.